France’s health regulatory body, the French National Agency for Medicines and Health Products Safety (ANSM), found that Biocon has failed to comply with good manufacturing practice requirements for 3 of its biosimilar products manufactured at the company’s Bommasandra facility in Bangalore, India.
France’s health regulatory body, the French National Agency for Medicines and Health Products Safety (ANSM), found that Biocon has failed to comply with good manufacturing practice requirements for 3 of its biosimilar products manufactured at the company’s Bommasandra facility in Bangalore, India.
In a non-compliance statement (NCS) issued on July 5, the ANSM identified a wide array of concerns with the drug product manufacturing activities for Biocon’s pegfilgrastim (Fulphila), trastuzumab (Ogivri), and insulin glargine (Semglee).
The French inspection, a pre-approval audit related to pending European Medicines Agency (EMA) marketing authorization applications for the 3 biosimilars, was conducted from March 13 to March 17 of this year. During the course of that inspection, the ANSM found 35 problems related to drug product manufacturing and quality control operations for the 3 biosimilars. Of those problems, the agency deemed the following 11 to be “major deficiencies:”
The agency recommended to the EMA that no batch of any of the 3 biosimilars that was manufactured prior to the issuance of the NCS should be supplied to the European marketplace. Furthermore, the agency proposed that the EU revoke the marketing authorization applications for all 3 products while the NCS remains in force.
ANSM has requested a follow-up inspection in order to ensure that the entirety of its recommendations to the facility have been implemented by the manufacturer, and to ensure that a robust quality system has been implemented.
In its statement on the ANSM’s findings, Biocon said that it would, “with its partner Mylan, work with the French and European regulatory authorities with regard to the follow-up inspection of the drug product facility and the Marketing Authorization Applications with the goal of an early re-inspection.” The company also noted that the ANSM had issued 2 compliance certificates for the company related to other inspections, and said that it was committed to ensuring the highest level of quality for all of its products.
That commitment aside, news of the NCS had a swift impact on Biocon’s stock price; shares of the company were down approximately 9.5% on Monday.
As Biocon works to address its manufacturing lapses for ANSM’s re-inspection, the FDA is still evaluating Biocon and Mylan’s trastuzumab (MYL-1401O), and regulatory action for the drug is expected in September of this year. If approved, this treatment will be the first biosimilar trastuzumab approved in the United States.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.